Purpose. Cardiac screening in adult kidney transplant candidates with myocardial perfusion scintigraphy (MPS) can reveal findings associated with increased risk for coronary heart disease events, but the exact value of this screening test is still undetermined. Methods. Narrative review based on the available literature and guidelines on the yield, benefits, and harms of MPS screening in kidney transplant candidates. Results. Although coronary angiography carries low risk in general population, it is not without risk particularly in patients with complex comorbid disease and the use of intravenous contrast media may precipitate a need for hospitalization and death. We could avoid invasive coronary angiography in patients with chronic kidney disease, although with high coronary calcium score, but good left ventricle function and normal perfusion, evaluated by Gated single-photon emission computed tomographic (SPECT) MPS. In fact, although Gated SPECT MPS has not a high sensitivity, it provides some variables that are closely related to sudden death: post-stress and rest-ejection fraction and left ventricular volumes, left ventricle muscle mass, extent of ischemia and scar. Conclusions. Gated SPECT MPS is a valid noninvasive cardiac screening test. It can be used as alternative to stress echocardiography in kidney transplant candidates with high cardiovascular risk and a positive or inconclusive exercise tolerance ECG test. Patients with abnormal perfusion and cardiac dysfunction should undergo invasive coronary artery imaging and endovascular treatment, while angiography could be avoided in patients with normal MPI, having good long-term prognosis.
Coronary artery disease, Kidney transplant, Myocardial scintigraphy
Financial support: No grants or funding have been received for this
Alberto Bestetti Casa di Cura San Pio X Via Nava, 31 20159 Milano, Italy firstname.lastname@example.org
Share this Article
Related Content In Arrhythmia
Update on Etripamil Nasal Spray for the At-home Treatment of Acute Paroxysmal Supraventricular Tachycardia
Heart International. 2021;15(1):Online ahead of journal publication
Paroxysmal supraventricular tachycardia (PSVT) defines a group of cardiac arrhythmias where the underlying mechanism is dependent upon structures at or above the level of the atrioventricular node. The recent PRE-EMPT study retrospectively evaluated health records of over 4.2 million people in the USA, estimating PSVT incidence at 73/100,000, and national prevalence at 168/100,000 (translating into […]
Rhythm Disorders in Endocrinology
European Journal of Arrhythmia & Electrophysiology. 2021;7(1):Online ahead of journal publication
Several closely regulated ion channels are involved in the various phases of the myocardial action potential (phases 0–4) (Figure 1).1 In the absence of neuroendocrine and other regulatory signals, the pacing rate of the sinoatrial node is 100 beats per minute (bpm). However, heart rate is not fixed, and varies along with cardiac output in order […]
Supraventricular Tachycardia: Electrocardiogram Diagnosis and Clinical Management for the Non-electrophysiologist
European Journal of Arrhythmia & Electrophysiology. 2021;7(1):Online ahead of journal publication.
Supraventricular tachycardia (SVT) occurs with a prevalence of 2–3/1,000 in the general population and is characterised by atrial rates >100 beats per minute (bpm) at rest. Per definition, SVT originates in the atria or atrioventricular (AV) node tissue above the His bundle.1,2 Diagnosis and clinical management of SVT have been the focus of recent European Society […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!